Mount Nebo Capital Invests in Cambrian Bio to Advance Longevity Health
Mount Nebo Capital announces its recent investment in Cambrian Bio, joining forces with Infinitas Capital, Korify Capital, and Apeiron Investment Group to revolutionize the field of longevity health. This strategic partnership underscores the commitment to advancing life science innovations that promise to extend the healthy human lifespan. Cambrian Bio, a leader in developing therapeutics targeted at the biological processes of aging, is set to redefine our approach to longevity and well-being. Cambrian Bio, a clinical-stage biotechnology company, is at the forefront of developing therapies that address aging at its biological roots, aiming to significantly extend the healthy human lifespan.
James Peyer, CEO of Cambrian Bio, articulates the company’s mission: “At Cambrian Bio, we are dedicated to unlocking the molecular mysteries of aging to prevent age-related diseases before they start. Our goal is to ensure that longevity equates to years lived in good health, not just longer life.”
The company's innovative approach includes the development of ATX-304, a cutting-edge pan-AMPK activator that improves cellular metabolism and shows promise in treating chronic diseases. Cambrian Bio’s commitment to groundbreaking solutions was recognized when it was named one of Fast Company’s Next Big Things in Tech, celebrating its impactful contributions to healthcare technology.
Tom Walsh and Andrew Musto, Founding Partners of Mount Nebo, shared: “The promise of longevity health technologies to expand our healthy years is not just a future concept but a present reality. At Mount Nebo, we are excited to support Cambrian Bio as they lead the way in making this future a tangible reality for everyone.”
With the backing of Mount Nebo and its partners, Cambrian Bio is poised to advance its pipeline of novel therapeutics. The company collaborates with leading scientists and top drug developers to efficiently bring effective treatments to market, aiming to deliver substantial benefits to patients globally. Through these strategic partnerships and innovative approaches, Cambrian Bio is setting new standards in medicine and public health.
